

# *Derbyshire Joint Area Prescribing Committee Annual Report*

## *April 2017 - March 2018*

[www.derbyshiremedicinesmanagement.nhs.uk](http://www.derbyshiremedicinesmanagement.nhs.uk)

Promoting Evidence-based, Cost-effective and Safe Prescribing

**April 2018**

*Authors*

Sadaf Qureshi – NICE Audit Pharmacist

Kate Stanley – Senior Administration Officer

## **Foreword**

Welcome to the annual report of Derbyshire Joint Area Prescribing Committee (JAPC), for the year 2017/2018. In it you will find an outline of our purpose, an overview of the outcomes of our work, and the volume of decisions taken.

JAPC has existed in its current format for over a decade and continues to work effectively in a collaborative manner across all commissioners and NHS Providers in Derbyshire, to ensure the safe, effective and efficient use of medicines in our system. In the current NHS financial climate the need for robust evidence-based medicine decision making is critical and JAPC (with its subgroups) provides assurance to the system in this regard.

Much of our work is “business as usual” in assessing new medicines and devices, reviewing existing guidelines and shared care agreements, and discussing safety concerns and reports. Another key role is to communicate these clearly across the system, via JAPC members, bulletins and the medicines management teams.

What has changed this year has been the emergence of the Regional Medicines Optimisation Committees ([RMOC](#)) that operates as a single national committee but meet in the NHS England regional footprints. The RMOCs make recommendations in relation to key topics, to which JAPC gives due regard. One key example has been to maximise the opportunities available by increasing the use of biosimilar biologic medicines. As a result of this, as well as our local financial pressures, we have set up a specific JAPC subgroup that is focussed on the effective use of biosimilar medicines as well as other hospital high-cost drugs. System performance has improved significantly in the use of biosimilars.

JAPC this year has also played a key role in local public consultations in relation to the provision of gluten-free foods on prescription, and the broader topic of self-care. This has been an interesting process to see through, and the position of JAPC covering the whole Derbyshire system helped this progress successfully.

As ever, JAPC would not function without the hard work of the clinical effectiveness team led by Slakahan Dhadli (JAPC Professional Secretary), as well as the skilful minute-taking by Adrian Thorpe. It also hinges on the commitment of all members and their skill in reading significant amounts of information so that we can get through the agendas in reasonable time. Thank you all.

Finally, I'd like to record our thanks to Sangeeta Bassi who left her post as Chief Pharmacist at Derbyshire Healthcare NHS Foundation Trust for her support to JAPC, and subsequently to welcome Steve Jones who replaces her. I'd also like to welcome Derby and Derbyshire Local Medical Committee (LMC) who have joined JAPC this year, via their Chief Executive Kath Markus. It is very helpful and constructive to have the LMC present to add value to our discussions.

Dr Andrew Mott  
GP and JAPC Chair

### **Key achievements in 2017-18**

1. *Twelve meetings were held during 2017-18.*
2. *181 medicines received a traffic light classification*
  - a. *37 drugs were classified as part of the monthly horizon scan*
  - b. *41 were new drug requests*
  - c. *70 drugs were classified based on NICE guidance*
  - d. *11 drugs were reclassified in-light of updated local guidance*
  - e. *22 drugs were reclassified*
3. *45 clinical guidelines were approved for use across Derbyshire*
4. *16 shared care agreements were approved for use across Derbyshire*
5. *26 Patient Group Directions were noted for use across Derbyshire.*
6. *26 Medicines Health Regulatory Authority drug safety alerts relevant for primary care were noted, and formulary/guidance updated to reflect the alert.*
7. *One patient safety alert was noted.*
8. *Formation of Biosimilar and High Cost Drug working group*
9. *Derbyshire JAPC/CCG representation at RMOC meetings*
10. *Continued support for improving cost effective work through the JAPC QIPP working group including:*
  - *Development of the gluten-free foods prescribing policies.*
  - *Development of self-care prescribing policy and planning to support implementation.*
  - *Appropriate local classification of drugs which should not be routinely prescribed*
  - *Development of the Vitamin D self-care position statement.*

## Introduction

### The purpose of the committee

JAPC is an important strategic network with the responsibility for promoting cost-effective use of medicines and medical devices and supporting functional integration in healthcare delivery. Each of its stakeholder organisations/bodies gains benefit from working in a co-ordinated manner.

### Aims of JAPC

JAPC is a strategic committee with responsibility for promoting appropriate, safe, rational, and cost-effective use of medicines and medical devices in Derbyshire. JAPC has delegated decision-making responsibility for pharmaceutical governance on behalf of Integrated Governance for the four Clinical Commissioning Groups (CCG) wholly within Derbyshire. Decisions represent standards of good practice and are normally expected to be implemented. JAPC has no delegated responsibility for resource allocation.

JAPC's key aims are:

1	To ensure high standards of pharmaceutical governance
2	To maintain a Derbyshire drug formulary
3	To maintain the traffic light classification that describes prescribing responsibility
4	To develop local clinical guidelines and shared care guidelines for AMBER classified drugs
5	To advise on implementation of NICE guidance/guidelines that concern drug use
6	To advise on the commissioning and provision of new drugs and new indications
7	To review key clinical trials and advise on their implications

### JAPC subgroups

JAPC oversees the work of the following subgroups:

- 1. Derbyshire Guideline Group** - an operational group that ensures that the CCGs commission drugs and develop guidelines that makes best use of NHS resources, to support clinically effective, cost effective, safe, evidence based, value for money prescribing of drugs and devices. The Guideline Group review the Derbyshire formulary on a monthly basis. Examples of work include development of the new asthma guidance for adults and children based on new NICE guidance, review of pharmaceutical rep requests for new drugs, update of clinical detailing aids used in educating clinicians and monthly reviews of each local formulary chapter.
  - 12 quorate meetings
- 2. JAPC QIPP working group** - The aim of the group is to develop Derbyshire wide guideline, policies and guidance to support self-care, reduce generation of unwanted repeat prescription items and reduction of waste medicines and to review difficult decisions including leading on development of prescribing policies.
  - 12 meetings held during 2017-18
- 3. Biosimilar and HCD working group** –The purpose of the Derbyshire Biosimilar & High Cost Drug (HCD) working group is to support Providers and Commissioner Organisations across the Derbyshire Sustainability and Transformation Partnership (STP) footprint to work collaboratively on maximising the system benefits available from the introduction of biosimilar medicines. The Biosimilar and HCD working group reviews biosimilar business case proposals and has clinical oversight of HCD clinical pathways that have been developed locally for discussion and approval at the Joint Area Prescribing Committee (JAPC). Two meetings have taken place during 2017-18. HCD commissioning algorithms were ratified for use across both Derbyshire providers Trusts; thereby providing commissioning intentions for HCDs. Examples of work undertaken includes agreement of HCD pathways.
  - 2 quorate meetings

**National committee:****Regional Medicines Optimisation Committees (RMOC)**

Four RMOC were set up for England (areas covered included London, the South, the North and Midlands and East of England) supported by four regional directors. The RMOCs are overseen by the Medicines Optimisation Oversight Group (MOOG), who are responsible for the governance, oversight of RMOC processes and the new RMOC system to ensure consistency in operation and for ratifying the prioritised RMOC annual work programme.

Derbyshire JAPC/CCGs are represented at the quarterly RMOC meetings.

**JAPC Prescribing Specification**

The prescribing specification is an essential component of the healthcare services contract commissioners (CCGs) have with NHS provider organisations. In Derbyshire this document outlines the role and responsibilities of our provider trusts in ensuring a transparent and collaborative approach to the safe and effective management of medicines, seamless care of patients transferring between NHS organisations and ensuring high quality prescribing. The document is updated annually for changes in process and best practice and taken to JAPC (with representatives from commissioner and provider organisations across Derbyshire) to ensure that its requirements are both fair and reasonable. Once agreed by JAPC, the specification is then included as part of the contract for main providers where Derbyshire CCGs are the host commissioners. The specification also applies to private serving NHS patients within Derbyshire.


**Membership**

JAPC comprises the following participating organisations:

- NHS Southern Derbyshire CCG
- NHS North Derbyshire CCG
- NHS Hardwick CCG
- NHS Erewash CCG
- Derbyshire Community Health Services NHS Foundation Trust (DCHSFT)
- Chesterfield Royal Hospital NHS Foundation Trust (CRHFT)
- Derby Teaching Hospitals NHS Foundation Trust (DTHFT)
- Derbyshire Healthcare NHS Foundation Trust (DHcFT)
- Public Health, Derby City and Derbyshire County Councils
- Derby & Derbyshire Local Medical Committee.

Membership of the committee comprises a wide variety of professional, clinical, commissioning, managerial, and organisational backgrounds.

# Derbyshire Joint Area Prescribing Committee Stakeholder map



## **Key decisions**

### **Prescribing specification for 2018-19**

Prescribing specification for 2018-19 underwent its annual update. The document outlines the role and responsibilities of local providers in ensuring a transparent and collaborative approach to safe and effective management of medicines, seamless care of patients between NHS organisations and ensuring high quality prescribing.

### **Items not routinely prescribed**

NHS England has taken action to reduce inappropriate prescribing of 18 medicines which will improve health and save millions of pounds a year. These items are deemed inappropriate for prescribing as more effective, safer and/or cheaper alternatives are available in primary care. Work has been undertaken locally to review and align the 18 NHSE recommended drugs to Derbyshire Traffic Light system and adjustments to the traffic light classification of these drugs has taken place and implementation continues.

### **Gluten-free foods**

Gluten-free foods were classified as BLACK, not routinely commissioned by Derbyshire CCGs. This decision was taken by the four Derbyshire CCG Governing Bodies in November/December 2017 and followed a period of consultation across Derbyshire. The governing bodies further endorsed the position statement, following the publication of the national gluten free food consultation as CCG's are allowed under NHS constitution to make their own decisions to best meet the needs of their population.

### **Vitamin D self-care statement**

Vitamin D self-care statement was developed, following recommendation from the JAPC working group. Prescribing of a short course of high dose Vitamin D for the correction of diagnosed deficiency in adults and children continues. However once the deficiency is reversed, patients are advised to continue self-care with Vitamin D for maintenance and insufficiency.

### **Self-care prescribing Policy**

Following the public consultation, the Self-care prescribing policy was agreed across Derbyshire. The Self-care prescribing policy sets out the Derbyshire Clinical Commissioning Groups' approach to ensure that prescribing of medicines and treatments that are available to purchase over-the-counter (and are used for the treatment of minor, short-term medical conditions, or have little evidence of benefit) is stopped and to support prescribers in implementing this decision. The self-care prescribing policy enables CCGs to manage demand, keep the NHS sustainable and protects essential services.

### **Introduction of rituximab (Truxima) biosimilar**

Local implementation and uptake of the rituximab biosimilar followed the conclusion of the procurement process and consultation with local specialist clinicians.

### **HCD commissioning algorithms**

New biologic treatments endorsed by NICE were included into the already agreed commissioning algorithms.

### **RED traffic light classification**

PrescQIPP published a report on tariff excluded high cost drugs and cytotoxic agents not appropriate for primary care prescribing and deemed 'high risk drugs'. 24 drugs from the list were classified as RED based on a PrescQIPP report.

### **Shared Care**

Following the publication of the British Society for Rheumatology for the monitoring of non-biologic disease-modifying anti-rheumatic drugs, all Derbyshire immunomodulating Shared Care monitoring arrangements were updated.

### **Freestyle Libre briefing statement**

Classified as - Brown after diabetic consultant/specialist initiation. Freestyle Libre sensors can now be prescribed in Derbyshire for patients with Type 1 diabetes according to strict criteria. The eligible cohorts of patients for Freestyle Libre were in line with the RMOC recommendations, and must show a benefit after 6 months of initiation to qualify for continued prescribing and are the subject of audit criteria as recommended by the Association of British Clinical Diabetologists.

## **Silk Garments**

Following publication of the long-awaited CLOTHES trial, JAPC reclassified silk garments from BROWN (exceptional use) to BLACK (not routinely recommended or commissioned). The CLOTHES trial concluded that there was no evidence of clinical or economic benefit in using silk garments compared with standard care in children with moderate to severe atopic eczema.

## **Emergency and quick start contraception**

The Faculty of Sexual and Reproductive Healthcare updated their advice on emergency contraception. The guidance was updated with general advice on how to decide whether to use ulipristal acetate or levonorgestrel. The guidance also included a guide on quick start contraception following emergency contraception depending on the type of hormonal contraception chosen.

## **Outpatient Parenteral Antimicrobial Therapy (OPAT) step up services**

OPAT step up service treatment guidelines were agreed for use across NDCCG and HCCG. The service provides intravenous antibiotics to patients outside of the acute hospital inpatient setting. In addition to the existing cellulitis pathway, the guidance now also includes antibiotic recommendations for respiratory tract infections and urinary tract infections.

## **Juxta Cures adjustable compression bandages**

JAPC reviewed the evidence for Juxta Cures and have agreed that there may be a small number of patients who are identified by the specialist vascular nurses or tissue viability specialists who may be trained to use the device and when access to nursing services is limited. Classified as BROWN after consultant/specialist initiation.

## **Interface between primary and secondary care**

The Derbyshire prescribing specification was updated following publication of the NHSE document regarding the interface between primary and secondary care. The document outlines the key national requirements for shared care agreements.

## **Communications**

All the JAPC recommendations, ratified minutes and publications are available at [www.derbyshiremedicinesmanagement.nhs.uk/home](http://www.derbyshiremedicinesmanagement.nhs.uk/home). This is a public-facing website. A JAPC Bulletin is issued every month, which is a concise outline of that month's JAPC decisions. This is distributed to all GP practices, non-medical prescribers, practice managers, medicine management teams and community pharmacies.

## **Summary**

The Derbyshire Joint Area Prescribing Committee continues to make good progress in bringing together clinical decision making and promoting the cost-effective use of medicines across the Derbyshire health economy. It has had excellent primary and secondary care representation, has been well attended, and delivers a significant improvement in governance associated with medicines use for all the participating organisations.

## **Recommendation**

The CCG Governing Bodies (or equivalent) of member organisations are requested to receive and acknowledge the details of this report.

## Appendix 1: Attendance

Name & title		Attendance
<b>Southern Derbyshire CCG</b>		
Dr A Mott (Chair from December 2013)	GP	11
Mr S Dhadli (Secretary)	Specialist Commissioning Pharmacist	11
Mr S Hulme	Director of Medicines Management	6
Mrs Sadaf Qureshi	NICE audit Pharmacist	11
Dr M Watkins	GP	8
Mrs L Hunter	Assistant Chief Finance Officer	9
Mrs H Murch	Acting Deputy Director of Medicines Management	5
<b>North Derbyshire CCG</b>		
Dr C Emslie	GP	10
Dr T Narula	GP	10
Mrs K Needham	Head of Medicines Management (& Hardwick CCG)	11
Ms M North (Deputy for K Needham)	Pharmacist, Medicines Management North (& Hardwick CCG)	1
Ms J Town	Head of Finance Commissioning	7
<b>Hardwick CCG</b>		
Dr T Parkin	GP	10
Mr M Scott	Chief Finance Officer	1
<b>Erewash CCG</b>		
Dr M Henn	GP	8
<b>Derby Teaching Hospitals NHS Foundation Trust</b>		
Dr W Goddard	Drugs & Therapeutics Committee Chair	10
Mr C Newman	Chief Pharmacist	5
Mr D Moore	Lead HCD Pharmacist	3
<b>Chesterfield Royal Hospital</b>		
Mr M Shepherd	Chief Pharmacist	9
Ms C Duffin (Deputy for M Shepherd)	Pharmacist	3
<b>Derbyshire Community Health Services</b>		
Ms A Braithwaite	Head of Medicines Management	5
Ms J Shaw (Deputy for A Braithwaite)	Principal Pharmacist	6
Mr G Crawshaw (Deputy for A Braithwaite)	Pharmacist	1
<b>Derbyshire Healthcare Foundation Trust</b>		
Dr S Taylor	Drugs & Therapeutics Committee Chair	6
Mrs B Thompson	Pharmacist	1
Ms S Bassi (until September 2017)	Chief Pharmacist (Interim)	3
Mr S Jones (from November 2017)	Acting Chief Pharmacist	2
<b>Derby City Council</b>		
Dr R Dewis	Consultant In Public Health Medicine	5
<b>Derby and Derbyshire Local Medical Committee</b>		
Dr K Markus (from December 2017)	Chief Executive	3

## Appendix 2: Drugs classified under the Traffic Light System (April 2017 – March 2018)

(New drugs are those that have not previously been classified in Derbyshire)

Black (46)	Brown (20)	Red (106)	Amber (1)	Green (8)
<i>Not routinely recommended or commissioned</i>	<i>Not recommended for use except in exceptional circumstances</i>	<i>Hospital/ specialist only</i>	<i>Shared care</i>	<i>Suitable for primary care</i>
Safinamide (New drug)	Fluticasone/vilanterol (Relvar) (reclassified in-light of updated guidance)	Idebenone (Raxone) (Monthly HS)	Dronedarone (Reclassify)	Insulin aspart (Fiasp) (new drug)
Elotuzumab (NICE TA434)	Indacaterol/glycopyrronium (Ultibro) (reclassified in-light of updated guidance)	Fibrinogen concentrate (FibCLOT) (Monthly HS)		Mometasone nasal spray (reclassified in light of updated guidance)
Tenofovir alafenamide (NICE TA435)	Formpterol/acridinium (Duaklir) (reclassified in-light of updated guidance)	Rituximab biosimilar (Truxima) (Monthly HS)		Fiasp Insulin (Reclassified)
Bevacizumab (NICE TA436)	Vilanterol/umeclidinium (Anoro) (reclassified in-light of updated guidance)	Ceftazidime + avibactam (Zavicefta) (Monthly HS)		Ceftazidime (Reclassified in light of updated guidance)
Ibrutinib with bendamustine and rituximab (NICE TA437)	Olodaterol/tiotropium (Spiolto) (reclassified in-light of updated guidance)	C1-esterase inhibitor (Cinryze) (Monthly HS)		Tafluprost and Timolol (Taptiqom) preservative free UDVs (Reclassified in light of updated guidance)
Alectinib (NICE TA438)	Linaclotide (reclassified in light of updated guidance)	Aminolevulinic acid hydrochloride (Ameluz) (Monthly HS)		Azithromycin 1% eye drops (Reclassified)
Pegylated liposomal irinotecan (NICE TA440)	Monuril (preferred cost-effective brand for fosfomicin) (Reclassified in light of updated guidance)	Cetuximab + Panitumumab (NICE TA439)		Fluticasone inhaler (children) (New drug)
Panitumumab (NICE TA240)	Calcium folinate (tablet for patients who cannot tolerate folic acid tablets) (Reclassified)	Daclizumab (NICE TA441)		Fluticasone + salmeterol (Seretide) (children) (New drug)
Silk Garments (reclassified)	Bimatoprost and Timolol (Ganfort) preservative free UDVs (Reclassified in light of updated guidance)	Ixekizumab (NICE TA442)		
Liothyronine (reclassify) (Hypothyroidism)	Juxta CURES (New drug)	Obeticholic acid (NICE TA443)		
Sodium Oxybate (reclassified)	Fusidic acid 1% eye drops (Reclassified)	Sodium Oxybate (Reclassified)		
Tofacitinib (HS)	Trimbow (Beclometasone + formoterol + glycopyrronium) (New drug)	Albutrepenonacog alfa (Monthly HS)		
Baricitinib (HS)	Sodium Chloride 7% nebulas (New drug)	Certolizumab pegol (NICE TA445)		
Afatinib (NICE TA444)	Capsaicin cream 0.025% (Reclassified)	Secukinumab (NICE TA445)		
Liraglutide (Saxenda) (New drug)	Freestyle Libre (Reclassified)	Tenofovir and emtricitabine (Monthly HS)		
Ciprofibrate (Reclassified)	Prednisolone soluble tablets (Reclassified)	Dabrafenib (Tafinlar) (Monthly HS)		
Dicycloverine (Reclassified)	Vilanterol + fluticasone + umeclidinium (Trelegy) (New drug)	Aztreonam (New drug)		
Vitamin B compound tablets (Reclassified)	MXL (once daily MR morphine) (New drug)	Bacillus Calmette-Guerin (B.C.G) (New drug)		
Bezlotoxumab (Zinplava) (Monthly HS)	Fluticasone inhaler (adults) (New drug)	Calc Folate (New drug)		

Meningococcal group B vaccine (Trumenba) (Monthly HS)	Fluticasone + salmeterol (Seretide) (New drug)	Colestilan (New drug)		
Naltrexone/Bupropion (Mysimba) (Monthly HS)		Dactinomycin (New drug)		
Ibrutinib (NICE TA452)		Desferrioxamine Mesilate (New drug)		
Bortezomib (NICE TA453)		Fampridine (New drug)		
Daratumumab with lenalidomide and dexamethasone (NICE TA454)		Filgrastim (New drug)		
Brodalumab (Pending NICE) (Monthly HS)		Icatibant Acetate (New drug)		
Ofatumumab (Monthly HS)		Lamivudine (New drug)		
Idelalisib with ofatumumab (NICE TA470)		Lenograstim (New drug)		
FreeStyle Libre (New drug)		Lipegfilgrastim (New drug)		
Prednisolone foam enema (Reclassified)		Mecasermin (New drug)		
Maviret (glecaprevir + pibrentasvir) (Monthly HS)		Mesna (New drug)		
Kisqali (Ribociclib) (Monthly HS)		Micafungin (New drug)		
Chloramphenicol ear drops (New drug)		Nitazoxanide (New drug)		
Tadalafil (once daily) (Reclassified)		Paritaprevir/Ritonavir/Ombitasvir (New drug)		
Mefenamic acid (Reclassified)		Pazopanib (New drug)		
Dosulepin (new patients) (Reclassified)		Pegfilgrastim (New drug)		
Gluten free products (Reclassified)		Ponatinib (New drug)		
Vismodegib (NICE TA489)		Sodium Benzoate (New drug)		
Guselkumab (Tremfya) (Monthly HS)		Sodium Phenylbutyrate (New drug)		
Naltrexone/Bupropion (Mysimba) (NICE TA494)		Telbivudine (New drug)		
Inegy (simvastatin + ezetimibe combination) (New drug)		Tretinoin (New drug)		
Fulvestrant (NICE 503)		Follitropin delta (Rekovel) (Monthly HS)		
Onexila XL (once daily MR oxycodone) (New drug)		Rolapitant (Varuby) (Monthly HS)		
Lesinurad (NICE TA506)		Pembrolizumab (Keytruda) (Monthly HS)		
Niraparib (Zejula) (Monthly HS)		Eliglustat (NHSE)		
Nusinersen (Spinraza) (Monthly HS)		Brentuximab vedotin (NICE TA446)		
Sodium hyaluronate + triamcinolone hexacetonide (Cingal) (Monthly HS)		Pembrolizumab (NICE TA447)		
		Etelcalcetide (NICE TA448)		
		Everolimus and sunitinib (NICE TA449)		
		Blinatumomab (NICE TA450)		
		Ponatinib (NICE TA451)		

		Liothyronine (cancer) (reclassified)		
		Calcium Folate (IV-for anaemia, neutropenia and poisoning) (Reclassified)		
		Adalimumab, etanercept and ustekinumab (NICE TA455)		
		Ustekinumab (NICE TA456)		
		Carfilzomib (NICE TA457)		
		Trastuzumab emtansine (NICE TA458)		
		Collagenase clostridium histolyticum (NICE TA459)		
		Adalimumab and dexamethasone (NICE TA460)		
		Roflumilast (NICE TA461)		
		Nivolumab (NICE TA462)		
		Eluxadoline (NICE TA471)		
		Asfotase alfa (HST6)		
		Cabozantinib (NICE TA463)		
		Olaratumab with doxorubicin (NICE TA465)		
		Baricitinib (NICE TA466)		
		Holoclar (NICE TA467)		
		Obinutuzumab with bendamustine (NICE TA472)		
		Cetuximab (NICE TA473)		
		Sorafenib (NICE TA474)		
		Dimethyl fumarate (NICE TA475)		
		Paclitaxel (NICE TA476)		
		Cladibrine (NICE TA493)		
		Mercaptamine (Monthly HS)		
		Brentuximab vedotin (NICE TA478)		
		Reslizumab (NICE TA479)		
		Tofacitinib (NICE TA480)		
		Basiliximab, Tacrolimus IR and Mycophenolate (NICE TA481 + 482)		
		Atezolizumab (Tecentriq) (Monthly HS)		
		Patiromer (Veltassa) (Monthly HS)		
		Sarilumab (Kevzara) (Monthly HS)		
		Telotristat etiprate (Xermelo) (Monthly HS)		
		Darunavir + cobicistat + emtricitabine + tenofovir alafenamide (Symtuza) (Monthly HS)		
		Aflibercept (NICE TA486)		
		Venetoclax (NICE TA487)		
		Regorafenib (NICE TA488)		

		Ibutinib (NICE TA491)		
		Levocarnitine (New drug)		
		Peginterferon alfa-2a (Pegasys) (Monthly HS)		
		Atezolizumab (NICE TA492)		
		Palbociclib with an aromatase inhibitor (NICE TA495)		
		Ribociclib with an aromatase inhibitor (NICE TA496)		
		Daptomycin (Cubicin) (Monthly HS)		
		Golimumab (NICE TA497)		
		Lenvatinib with everolimus (NICE TA498)		
		Glecaprevir - pibrentasvir (NICE TA499)		
		Certitinib (NICE TA500)		
		Ibrutinib (NICE TA502)		
		Autologous CD34+ enriched cell fraction (Strimvelis) (HST7)		
		Pirfenidone (NICE TA504)		
		Ixazomib with lenalidomide and dexamethasone (NICE TA505)		
		Sofosbuvir + velpatasvir + voxilaprevir (Vosevi) (NICE TA507)		
		Eliglustat (Cerdelga) (HST5)		
		Tilmanocept (Lymphoseek) (Monthly HS)		
		Glycerol phenylbutyrate (Ravicti) (Monthly HS)		
		Rilpivirine + emtricitabine + tenofovir alafenamide (Odefsey) (Monthly HS)		
		Dupilumab (Dupixent) (Monthly HS)		

### Appendix 3: Clinical guidelines, shared care agreements and PGDs ratified between April 2017-March 2018

Date of meeting	Title	Guideline/SCA /PGD	Update, review or new
April 2017	Management of Infective Exacerbation of Bronchiectasis in Adults in Primary Care	Guideline	Review
	Gastro-oesophageal Reflux Disease: Recognition, Diagnosis and Management in Children and Young People	Guideline	Review
	NSTEMI Guidance – North Derbyshire	Guideline	Review
	Management of Recurrent Urinary Tract Infections (RUTIs) in Adult Females	Guideline	Review
May 2017	Asthma for children and adults	Guideline	Review
	Management of Clostridium difficile Infection in Primary Care	Guideline	Review
	Adult lipid modification therapy in non-familial (non-FH) hyperlipidaemia	Guideline	Review
	Identification and management of familial hypercholesterolaemia (FH)	Guideline	Review
	<a href="#">Cinacalcet in primary hyperparathyroidism</a>	SCA	Review
	<a href="#">Nebulised colistimethate injection (Colomycin®) in pseudomonas aeruginosa lung infections in adults with bronchiectasis (non-cystic fibrosis)</a>	SCA	Review
	<a href="#">Administration of low dose diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) to women from 16 weeks of pregnancy in accordance with the pertussis vaccination for pregnant women national immunisation programme</a>	PGD	NA
June 2017	Bisphosphonate Length of Treatment Guideline in Osteoporosis	Guideline	Review
	Management of Chronic Obstructive Pulmonary Disease (COPD)	Guideline	Review
	Continence Appliance Prescribing	Guideline	Review
	Prevention, Diagnosis and Management of Vitamin D Deficiency in Primary Care	Guideline	Review
	Children's Referral Guideline for Sub-Lingual ImmunoTherapy (SLIT) – Grass Pollen Extract (Grazax)	Guideline	Review
	Managing Behavioural Problems in Patients with Dementia (BPSD)	Guideline	Review
	<a href="#">Degarelix for the treatment of adult male patients with advanced hormone-dependant prostate cancer</a>	SCA	Review
	<a href="#">Methotrexate</a>	SCA	Review
	<a href="#">Lithium</a>	SCA	Review
	<a href="#">Shingles vaccine as per national programme</a>	PGD	NA
	<a href="#">Pneumococcal vaccine for those at high risk of pneumococcal disease</a>	PGD	NA
	<a href="#">Meningococcal ACWY vaccine as per national programme</a>	PGD	NA
	<a href="#">Rotavirus vaccine as per childhood vaccination programme</a>	PGD	NA
July 2017	Treatment of refractory symptomatic chronic constipation in men and women	Guideline	Review
	Management of emergency contraception	Guideline	Review
	Primary Care Management of Irritable Bowel Syndrome	Guideline	Review
	Melatonin guidance for the treatment of sleep disorders in children with neurodevelopment disorders	Guideline	Review
August 2017	Liothyronine position statement	Guideline	Review
	Cabergoline and quinagolide for hyperprolactinaemia	Guideline	Review
	Oral Fosfomycin for the Treatment of Uncomplicated Lower Urinary Tract Infections by multi resistant bacteria	Guideline	Review
	Treatment of Chronic Open Angle Glaucoma and Ocular Hypertension	Guideline	Review
	North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care	Guideline	Review
	<a href="#">Ciclosporin</a>	SCA	Review

	<a href="#">Sulfasalazine</a>	SCA	Review
	<a href="#">Acamprosate and disulfiram (Derbyshire County)</a>	SCA	Review
	<a href="#">Amoxicillin, flucloxacillin, phenoxymethylpenicillin (Pen V), trimethoprim, nitrofurantoin, codeine phosphate and paracetamol for use in Derby Urgent Care Centre</a>	PGD	NA
	<a href="#">Levonorgestrel in emergency contraception</a>	PGD	NA
September 2017	<a href="#">Management of Dyspepsia and Gastro-oesophageal Reflux Disease (GORD)</a>	Guideline	Review
	<a href="#">Azathioprine/6-mercaptopurine for patients aged 16+ years</a>	SCA	Review
	<a href="#">Sodium Aurothiomalate (Myocrisin® Gold Injection)</a>	SCA	Review
	<a href="#">Leflunomide</a>	SCA	Review
	<a href="#">Influenza vaccine nasal spray suspension (Fluenz Tetra®▼)</a>	PGD	NA
	<a href="#">Influenza vaccine as per national programme</a>	PGD	NA
	<a href="#">Hexavalent combination DTaP/IPV/Hib/HepB vaccine for individuals from six weeks (routinely 8 weeks) to under ten years of age – update of existing PGD</a>	PGD	NA
	<a href="#">DTaP/IPV/Hib vaccine for individuals from three years and four months to under ten years of age</a>	PGD	New
October 2017	<a href="#">Monitoring and Medication following Bariatric Surgery</a>	Guideline	New
	<a href="#">Requesting Prescriptions for and Managing Patients using Varenicline</a>	Guideline	New
	<a href="#">D-penicillamine</a>	SCA	Review
	<a href="#">Riluzole for the treatment of the Amyotrophic Lateral Sclerosis form of Motor Neurone Disease</a>	SCA	Review
	<a href="#">Administration of intramuscular (or subcutaneous) inactivated influenza vaccine</a>	PGD	NA
	<a href="#">Supply and administration of live attenuated influenza vaccine nasal spray suspension (Fluenz Tetra®▼)</a>	PGD	NA
	<a href="#">Hepatitis A Vaccine – Adult</a>	PGD	NA
	<a href="#">Hepatitis A Vaccine – Children</a>	PGD	NA
	<a href="#">Typhoid Vaccine for Children and Adults</a>	PGD	NA
	<a href="#">Hepatitis A and Typhoid Vaccine</a>	PGD	NA
	<a href="#">Hepatitis B</a>	PGD	New
	<a href="#">Vitamin K</a>	PGD	NA
November 2017	<a href="#">Oral Anticoagulation with Warfarin</a>	Guideline	Review
	<a href="#">Pharmacological Treatment of Premature Ejaculation</a>	Guideline	Review
	<a href="#">Prescribing for Oral Thrush in Babies and Prescribing for Surface and Ductal Thrush in Lactating Women</a>	Guideline	Review
	<a href="#">Dronedaron for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF)</a>	SCA	New
	<a href="#">Administration of low-dose diphtheria, tetanus and inactivated poliomyelitis vaccine (Td/IPV) to individuals from 10 years of age</a>	PGD	NA
	<a href="#">Administration of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (DTaP/IPV or dTaP/IPV) to individuals from three years four months to under ten years of age</a>	PGD	NA
December 2017	<a href="#">Emollient Prescribing Guide</a>	Guideline	New
	<a href="#">Derbyshire Nebuliser Guidelines for COPD patients: assessment and initiation</a>	Guideline	Review
	<a href="#">Management of Neuropathic Pain in Primary Care</a>	Guideline	Review
	<a href="#">Advisory guidance on when to initiate gastroprotection with a NSAID (or antiplatelet)</a>	Guideline	Review
	<a href="#">Liothyronine for the treatment resistant depression</a>	SCA	Review
	<a href="#">Ulipristal Acetate 30mgs (EllaOne®) for Sexual Health Patients aged 13 years and older</a>	PGD	NA
January 2018	<a href="#">Primary Care Management of Overactive Bladder</a>	Guideline	Review
	<a href="#">Ophthalmology commissioning pathways for age related macular degeneration; macular oedema due to BRVO and CRVO; diabetic macular oedema and non-infectious posterior uveitis</a>	Guideline	Review

February 2018	Management of Non-Malignant Chronic Pain in Primary Care	Guideline	Review
	Referral guide for Allergic Rhinitis in Adults and Adolescents over 12 years of age	Guideline	Review
	Menopause Management	Guideline	Review
	Oxygen	Guideline	Review
	Treatment of Severe Psoriasis in Adults (secondary care)	Guideline	New
	Administration of Hepatitis B vaccine to individuals pre- and post-exposure to hepatitis	PGD	Review
	Administration of Hepatitis B vaccine to renal patients	PGD	Review
March 2018	Administration of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV)	PGD	Review
	Asthma management in adults $\geq 17$ years	Guideline	New
	Asthma management for children and young people aged 5 to 16 years and children under 5 years	Guideline	New
	Chlamydia Testing and Management: A Framework for Derbyshire	Guideline	Review
	Oral fosfomycin for the treatment of multi-resistant UTIs	Guideline	Review
	Acute Coronary Syndrome/NSTEMI guideline	Guideline	Review
	Naltrexone for the maintenance of alcohol abstinence	SCA	Review
Administration of measles, mumps and rubella (MMR) vaccine	PGD	NA	

#### **Appendix 4: MHRA Drug safety alerts:**

All MHRA drug safety alerts are tabled at JAPC and Guideline Group (and at Provider Trust), but only those relevant to primary care are highlighted

<b>Date</b>	<b>Alert</b>	<b>Type of alert</b>	<b>Action undertaken</b>
April 2017	SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)	MHRA	Update of diabetes guidance and formulary chapter
	Launch of pilot reporting scheme for harms associated with illicit drugs, particularly new psychoactive substances	MHRA	Noted
May 2017	Valproate and neurodevelopmental disorders: new alert asking for patient review and further consideration of risk minimisation measures	MHRA	Formulary updated. Included in JAPC bulletin and MM newsletter
	Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy	MHRA	Noted
	Resources to support the safety of girls and women who are being treated with valproate	Patient safety alert	Formulary updated. Included in JAPC bulletin and MM newsletter.
June 2017	Finasteride: rare reports of depression and suicidal thoughts	MHRA	Noted
	New CPD e-learning module on reporting suspected adverse drug reactions	MHRA	Noted
July 2017	Denosumab (Prolia, Xgeva ▼): reports of osteonecrosis of the external auditory canal	MHRA	Guidance updated
	Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin	MHRA	Formulary updated
	Pseudoephedrine and ephedrine: regular review of minimising the risk of misuse in the UK	MHRA	Noted
	e-cigarettes and refill containers (e-liquids): report suspected side effects and safety concerns	MHRA	Noted
September 2017	Corticosteroids: risk of central serous chorioretinopathy with local as well as systemic administration	MHRA	Formulary updated
	Adrenaline auto-injectors: updated advice after European review	MHRA	Formulary updated
October 2017	Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin	MHRA	Noted
	Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse	MHRA	Noted
November 2017	Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy	MHRA	Noted
	Gabapentin (Neurontin): risk of severe respiratory depression	MHRA	Guidance updated
	Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido	MHRA	Noted
	Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus	MHRA	Formulary and guidance updated
December 2017	Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions	MHRA	Formulary updated
	Oral tacrolimus products: reminder to prescribe and dispense by brand name only	MHRA	Noted
	Antiepileptic drugs: updated advice on switching between different manufacturers' products	MHRA	Noted
	Updates to Public Health England's Green Book chapter on live attenuated vaccines	MHRA	Noted
February 2018	Drug-name confusion: reminder to be vigilant for potential errors	MHRA	Noted
	Co-dydramol: prescribe and dispense by strength to minimise risk of medication error	MHRA	Formulary updated
	Herbal medicines: report suspected adverse reactions via the Yellow Card Scheme	MHRA	Noted
March 2018	Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients	MHRA	Traffic lights updated